Foundayo isn't specifically licensed or clinically trialled for PCOS, and as a medicine that only launched in the UK in August 2026, there's currently no published research — not even the smaller retrospective studies that exist for some other GLP-1 medicines — evaluating orforglipron specifically in people with PCOS. However, Foundayo is licensed for weight management (BMI 30+, or 27–30 with a weight-related condition) and for type 2 diabetes, and many women with PCOS meet these standard eligibility criteria, given how closely PCOS is linked with insulin resistance and weight gain. Any PCOS-related benefit would work indirectly, through weight loss and improved insulin sensitivity, rather than through a targeted PCOS treatment mechanism.
It's important to be upfront here. Foundayo is licensed in the UK for weight management in adults meeting standard BMI criteria, and separately for improving blood sugar control in type 2 diabetes — you can check where you stand with our BMI calculator and our Foundayo eligibility guide. It is not licensed specifically for PCOS. Because Foundayo only launched in the UK in August 2026, it doesn't yet have the kind of smaller retrospective studies or case series that have started to emerge for more established GLP-1 medicines used off-label in PCOS — this is a genuinely earlier-stage picture than exists for those medicines, not a gap unique to Foundayo's PCOS potential specifically.
What this means in practice
If you have PCOS and are considering Foundayo, your eligibility will be assessed against the standard weight-management or diabetes criteria — not a PCOS-specific pathway, because no such pathway currently exists for any GLP-1 medicine, and even less dedicated research exists for Foundayo specifically than for other options. Many women with PCOS do qualify under these standard criteria, since PCOS is strongly associated with both excess weight and insulin resistance.
| Treatment | Licensed for PCOS? | PCOS-specific evidence |
|---|---|---|
| Foundayo | No — weight management and type 2 diabetes only | None published yet; launched in the UK in August 2026 |
| Mounjaro | No — weight management and type 2 diabetes only | Smaller retrospective studies, including one of 56 women with around 9.5% average weight loss; no dedicated trials sponsored by the manufacturer |
| Wegovy | No PCOS-specific pathway exists for any GLP-1 medicine | See our Wegovy and PCOS guide for the evidence on that treatment |
| Metformin | Long-established insulin-sensitising treatment for PCOS | Decades of research behind it, with a modest and inconsistent effect on weight |
It helps to know the numbers here. PCOS is genuinely common, affecting an estimated 5 to 10% of women of reproductive age, making it the most common endocrine condition in this group, and insulin resistance is present in a substantial majority of cases — documented in clamp studies in around 75% of women with PCOS. This creates a genuinely difficult cycle: insulin resistance contributes to weight gain, and excess weight in turn worsens insulin resistance and other PCOS symptoms, including irregular periods and elevated androgen levels. Breaking this cycle through weight loss is one of the most consistently recommended first-line approaches for managing PCOS, particularly in women who are overweight or living with obesity.
While there's no dedicated Foundayo research in PCOS yet, some reasonable inference is possible from two angles: Foundayo's own licensed trial data, and the wider evidence base on GLP-1 medicines in PCOS more generally.
Foundayo's Own Weight-Loss and Diabetes Evidence
Foundayo's ATTAIN-1 trial showed average weight loss of 11.1% at 72 weeks at the highest approved dose (see our Foundayo before and after guide for the full picture), and its ACHIEVE trial programme for type 2 diabetes — covered in our guide to Foundayo and type 2 diabetes — showed meaningful improvements in insulin resistance markers alongside blood sugar control. Since weight loss of just 5% or more is associated with measurable improvements in insulin resistance, ovulatory function and cardiometabolic risk markers in women with PCOS specifically, Foundayo's demonstrated weight-loss and insulin-related effects in its licensed trials provide a reasonable, if indirect, basis for expecting some benefit in PCOS — even without dedicated research confirming this.
What Other GLP-1 Medicines Show in PCOS
Smaller studies of tirzepatide (Mounjaro) in women with PCOS have reported encouraging results, including average weight loss of around 9.5% and significant improvements in insulin resistance in a retrospective study of 56 women — our Mounjaro and PCOS guide sets this out in detail. Since Foundayo works through the same broad GLP-1 pathway (explained in how Foundayo works) — albeit as a single-mechanism medicine rather than tirzepatide's dual GIP/GLP-1 action — there's a reasonable, though unconfirmed, basis to expect some similar benefit, pending dedicated Foundayo-specific research.
Important
This entire section is reasonable inference, not established evidence specific to Foundayo. Treat it as context for a conversation with your prescriber, not as confirmation of how Foundayo will perform for PCOS specifically. This guide will be updated as dedicated research emerges.
| Possible improvement | How it would come about | Evidence status for Foundayo |
|---|---|---|
| Weight loss | The main route through which most PCOS-related benefits are thought to occur with any GLP-1 medicine | Shown in Foundayo's licensed trials (ATTAIN-1); not studied in PCOS |
| Improved insulin sensitivity | Follows weight loss and may reduce the long-term type 2 diabetes risk that's elevated in PCOS | Inferred from its diabetes trial data; not confirmed in PCOS |
| More regular periods | May follow as weight and insulin resistance improve, as seen with other approaches and GLP-1 medicines | Not confirmed for Foundayo |
| Fewer androgen-related symptoms | An indirect effect as metabolic markers improve, not a targeted mechanism | Not confirmed for Foundayo |
It's worth being realistic that Foundayo doesn't treat PCOS directly — it isn't a hormonal therapy targeting the condition's reproductive features. Any benefit is understood to work through weight loss and improved insulin sensitivity, which happen to be central drivers of PCOS symptoms for many women.
For most women managing PCOS alongside excess weight, the most evidence-backed and realistic approach combines several elements rather than relying on medication alone: dietary changes (particularly reducing refined carbohydrates, which can worsen insulin resistance), regular physical activity, and medication where clinically appropriate. Foundayo, where eligible, may be a genuinely useful part of this picture, particularly given the meaningful weight loss shown in its licensed trials — see our dedicated nutrition guide for dietary principles that support insulin sensitivity alongside GLP-1 treatment — but it works best as one part of a broader approach rather than a standalone fix for PCOS. If you do start, our Foundayo dosage and titration guide and side effects guide explain what to expect.
Metformin and Established PCOS TreatmentMetformin has long been the standard insulin-sensitising treatment for PCOS, and it remains well-established with decades of research behind it. Metformin's effect on weight loss specifically is often described in the research literature as modest and inconsistent, which is part of why interest in GLP-1 medicines has grown across the class generally. However, metformin's much longer track record, lower cost, and dedicated PCOS-specific evidence base remain genuine advantages worth weighing against a newer medicine like Foundayo, which simply hasn't had the same length of time to build a comparable evidence picture for this specific condition.
Fertility Considerations Worth KnowingIf you're managing PCOS and considering pregnancy in the near future, this is an important conversation to have before starting Foundayo, not after. Foundayo isn't recommended during pregnancy, and because PCOS itself is linked with fertility challenges, some women may find that improved insulin sensitivity and weight loss actually increase the chance of becoming pregnant while on treatment — which is exactly why reliable contraception is worth discussing with your prescriber if pregnancy isn't your current goal. Foundayo can also reduce the absorption of oral hormonal contraceptives around the start of treatment and each dose increase; our Foundayo side effects guide covers the timing windows. If you are actively trying to conceive, this is worth raising openly during your consultation so your prescriber can advise on the right approach and timing.
Discuss Your Full Health Picture With Our Team
Our GPhC-registered pharmacy team can talk through your eligibility for Foundayo, including how PCOS and related insulin resistance fit into your overall assessment.
Start Your Free Online Consultation → Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- Foundayo® (orforglipron) Summary of Product Characteristics, MHRA Products website.
- Wharton S, et al. ATTAIN-1. N Engl J Med, September 2025.
- Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome. Retrospective observational study.
- NHS. Polycystic ovary syndrome (PCOS): overview, symptoms and treatment.
- The Potential Utility of GLP-1 Receptor Agonists for the Management of Polycystic Ovary Syndrome. PMC, National Institutes of Health.